IRVINE, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness
and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports
nutrition, and pharmaceutical products, announced today that its Chief Executive Officer and Founder, Frank Jaksch, will present at
the Rodman & Renshaw 18th Annual Global Investment Conference. The investor conference
will be held on Sept. 11-13, 2016 at the Lotte New York Palace Hotel in New York, N.Y.
Mr. Jaksch is scheduled to present on Tuesday, Sept. 13 at 3:50 p.m. Eastern Time. ChromaDex management will also be attending
one-on-one meetings with institutional investors throughout the day.
The Rodman & Renshaw 18th Annual Global Investment Conference will feature more than 300 public & private companies from around
the world presenting to an anticipated audience of over 2,000 attendees. The Conference will feature tracks devoted to
Biotechnology & Healthcare, Natural Resources, CleanTech, Technology, Media & Telecommunications companies and include corporate
presentations with Q&A sessions, investor one-on-one meetings and daily networking opportunities.
About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary
ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to
our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as
"phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix
Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a
spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more
about ChromaDex, please visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical
facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should",
"could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in
this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the
risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended January 2, 2016, ChromaDex's Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the
SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances
after the date hereof.
ChromaDex Company Contact: Andrew Johnson Director of Investor Relations 949-419-0288 andrewj@chromadex.com
